Navigation Links
Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases
Date:8/3/2009

Philadelphia, PA, 3 August 2009 A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.

Dr. Robert L. Avery of Santa Barbara, Calif., discusses issues related to the use of antibodies against vascular endothelial growth factor (VEGF) in pediatric ophthalmology. The two anti-VEGF antibodies available so farbevacizumab and ranibizumabhave been rapidly adopted for the treatment of age-related macular degeneration (AMD), the leading cause of vision loss in older adults. The antibodies work by blocking the development of new blood vessels (angiogenesis).

Anti-VEGF antibodies were originally approved for use in cancer treatment, and there have been some safety concerns, including a possible increase in stroke risk. However, at the much smaller doses used in eye diseases, the two antibodies appear to be safe. However, in discussing the growing use of anti-VEGF antibodies in children, Dr. Avery sounds a cautious note. One study, also published in the August Journal of AAPOS, found that bevacizumab treatment in one eye of a child with eye disease also improved the condition in the other eye. This, along with other limited reports, suggests that the antibodies might leave the eye and enter the bloodstream, where they could potentially lead to side effects and complications.

Side effects are a special concern in children, who might be at higher risk because of their smaller size. Used in premature infants with an eye disease called retinopathy of prematurity, anti-VEGF antibodies could have the potential for harm to still developing organs.

These issues are particularly difficult because the anti-VEGF antibodies are not approved for use in chi
'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Study, meta-analysis examine factors associated with death from heatstroke
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
5. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
6. Researchers genetically engineer micro-organisms into tiny factories
7. Study Downgrades Gene as Heart Risk Factor
8. Severe heart defect likely caused by genetic factors
9. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
10. Aggressively Treating Cardiac Risk Factors May Reverse Ischemia
11. New peptide communication factor enabling bacteria to talk to each other discovered

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...RUZ, CA--New connections begin to form between bra... task, according to a study published this week in... California, Santa Cruz, the study involved detail...e place in the brain during motor learning. , Th... reach through a slot to get a seed. They observed...
(Date:11/29/2009)...s unaware the sleep disorder boosts urine producti...althDay News) -- People who wake up during the nig...ogical problem. Sleep apnea, a breathing-related s...y suggests that nighttime urination, or nocturia, ...ructive sleep apnea, a disorder in which soft tiss...
(Date:11/28/2009)..., CHICAGO, Nov. 28 Get ready for...e in the clinical routine when Siemens introdu...sembly and Annual Meeting of the Radiological Soci...cember 3 at McCormick Place (Booth #825, East Buil...syngo. via , Siemens, new imaging software fo...
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/ -..."), a supplier of precision technology products an...nnual meeting of the Company,s shareholders has be... and location of the meeting will be announced in ...received a requisition notice from Stephen Bershad...
(Date:11/27/2009)...SAN FRANCISCO, Nov. 27 T... that Blair Lambert, CFO/COO, will present at the ...ld at the May Fair Hotel in London, England, on We..., To listen to a live broadcast of The Gymboree Co... log on to www.gymboree.com, click on "Our Company...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2
...f investigators led by St. Jude Children’s Researc...treatment of the childhood brain cancer medullobla...urvival of children with this disease. The t... and raised the rate of survival among the 48 high...
People who have a low response to alcohol or the so called ability to
...edicine as a specialty in New Zealand may no longe...ecommendation by the Medical Council comes into fo...opportunity of working with breast physicians unde... are unable to seek employment in breast clinics. ...
... proposal for prevention of chikungunya and dengue...rectorate of Public Health//. Aedes aegypti, m...causing virus and dengue causing virus. Hence, the...e will be examined. According to P. Padmanabha...
...D--A dart-like molecule that sticks to proteins in...wth of blood vessels, according to researchers at... Clinic Cole Eye Institute. //Uncontrolled blood v...r 65 in the United States. Robert Salomon and...
... inactivity, depression and falls all increase ris...rgeting falls may be a particularly effective way ...ding to a new study. Fall-prevention efforts ...ers led by Vicki Freedman, Ph.D., a professor at t...
Other Medicine News:Health News:Improved Treatment Raises Medulloblastoma Survival Rate 2Health News:Molecule responsible for age associated macular degeneration identified 2Health News:Preventing Falls May Be Key to Avoiding Disability in Elderly 2
(Date:11/25/2009)... , EXTON, Pa., Nov. 25 BioTren...aunchTrends(TM) : Stelara report, the first i... tracking the launch of Centocor Ortho-Biotech,s S...months of availability. Each wave of the report p...rmatologists and qualitative information from a su...
(Date:11/25/2009)... , BASKING RIDGE, N.J., Nov. 25 /PRNewswire/ -...ding the development of antithrombotic aptamers wi...zo, PhD, CEO and President, will be presenting at ...ce at the New York Palace Hotel in New York City. ...(EST) on Tuesday, December 1 and will include an o...
(Date:11/25/2009)... , EAST BRUNSWICK, N.J., Nov. 25 /PRNewswire...cturer of direct digital Radiography ( ddR ) syste...acquired by a private Swiss Investor with a long t...g brand. The acquisition included all assets and i...entory. After 25 years of success and growth Swiss...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Swissray International Announces New Ownership 2Obesity Contributes to Rapid Cartilage Loss 51575 1Obesity Contributes to Rapid Cartilage Loss 51575 2Obesity Contributes to Rapid Cartilage Loss 51575 3Obesity Contributes to Rapid Cartilage Loss 51575 4Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 1Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 2Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 3Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 4Simulating medical situations helps students learn retain basic science concepts 51568 1Simulating medical situations helps students learn retain basic science concepts 51568 2
...Shows ADHD Patch Provides Tolerable and Effective ... SHP, Nasdaq:,SHPGY, TSX: SHQ), the global special...from a 12-month study of DAYTRANA(TM) (methylpheni...peractivity Disorder (ADHD),patch, demonstrated th...,and symptom control improvement in children aged ...
...umor Activity of NKTR-102 Associated With Increase... Active Metabolite of Irinotecan, SAN FRANCISCO, ...ented positive preclinical data today on its propr... at the AACR-NCI-EORTC,International Conference in...lighted the anti-tumor activity and unique pharmac...
Other Medicine Technology:Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 2NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 3NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 4NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 5
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: